Based on intent-to-treat efficacy data, the proportions of MTX-treated patients who achieved ACR20, ACR50, DAS28 employing C-reactive protein (DAS28-CRP) response, and DAS28-CRP scores <2.6 and <3.2 were consistent through week 256.
To improve treating efficacy, they are also developed into more functional drug delivery nanosystems.
The agreement between the according-to-protocol and the intention-to-treat efficacy analyses strengthens these findings.
Intent-to-treat efficacy analysis showed an overall response rate of 46%.
We considered the intent-to-treat efficacy as the weighted average of the efficacy for full schedule and the efficacy for partial schedule and used that to estimate the effectiveness of a partial schedule.
Adapted from the NCKP trial of PCV7 [ 23]; 94% (intent-to-treat) efficacy against covered serotypes, with PCV7 coverage of approximately 80% against S.pneumoniae serotypes that cause pneumococcal meningitis and bacteremia.
All randomized subjects who received at least 1 dose of study medication and had baseline and at least 1 postbaseline day of diary data were included in the primary intent-to-treat efficacy analyses.
Intention-to-treat efficacy analysis included all randomized subjects who received at least one dose of imeglimin or placebo and provided a baseline and at least one postbaseline A1C value.
The Intention-To-Treat efficacy analysis set (ITTe) will include all subjects who were randomized to the study and at the time of screening were treated with metformin plus a sulfonylurea and had a screening HbA1c of ≥ 7.5%, and received at least one dose of study treatment (either Cycloset™ or placebo).
The median number of chemotherapy cycles received by the ITT and evaluable groups was 5.7 and 5.9, respectively (Table 2).> -wrap-foot>> -wrAbbreviationsECOGtions: Eastern Cooperative Oncology Group Group aHer-2 expression was determined by immunohistochemical staining *ITT: intent-to-treat Efficacy analyses were based on the total patients enrolled (i.e. the evaluable and ITT populations).
For final intent-to-treat efficacy analysis, response rate, TTP, PFS, OS, the 28 patients whose platinum sensitivity status on enrolment was unknown on initial review, but later resolved, were appropriately added back to either the platinum-sensitive or -resistant/refractory patient populations.
